Yanzhong Huang, Ph. D.
Senior Fellow for Global Health, Council on Foreign Relations; Professor, School of Diplomacy and International Relations, Seton Hall University

Yanzhong Huang is professor and director of global health studies at Seton Hall University's School of Diplomacy and International Relations. He is also a senior fellow for global health at the Council on Foreign Relations, where he directs the Global Health Governance roundtable series and co-directs the China and Global Governance project. He is the founding editor of *Global Health Governance: The Scholarly Journal for the New Health Security Paradigm*. He has written extensively on China and global health.

Dr. Huang has published numerous reports, journal articles, and book chapters, including articles in *Survival*, *Foreign Affairs*, *Public Health*, *Bioterrorism and Biosecurity*, and *Journal of Contemporary China*, as well as op-ed pieces in the *New York Times*, *International Herald Tribune*, *YaleGlobal*, and *South China Morning Post*, among others. He is the author of *Governing Health in Contemporary China*. His current research focuses on China's environmental health politics and its role in global governance. In 2012, he was listed by *InsideJersey* magazine as one of the "20 Brainiest People in New Jersey." He was a research associate at the National Asia Research Program, a public intellectuals fellow at the National Committee on U.S.-China Relations, an associate fellow at the Asia Society, a visiting senior research fellow at the National University of Singapore, and a visiting fellow at the Center for Strategic and International Studies.

Dr. Huang testified before the Commission in April 2014 on "China's Healthcare Sector, Drug Safety, and the U.S.-China Trade in Medical Products."

Questions for Panelist

- How has China's market for pharmaceutical, health, and biotech firms changed in the last five years? What are the drivers of these changes?
- How, if at all, does the Chinese government support the development of its health, biotech, and pharmaceutical industries?
- To what extent do U.S. medical, biotech, and health firms have access to the Chinese market?
- What challenges do U.S. health firms face when selling into the Chinese market and in what ways, if any, have those challenges evolved in recent years? How have U.S. businesses responded to these challenges?
- What regulatory burdens exist for foreign pharmaceutical, biotech, and other medical good and service providers seeking to operate in China?
- To what extent are pharmaceutical intellectual property rights enforced in China? What issues, if any, do foreign pharmaceutical companies face protecting their IP in China?
- The Commission is mandated to make policy recommendations to Congress based on its hearings and other research. What are your recommendations for Congressional action related to the topic of your testimony?